BioNotebook: Amarin, Sucampo/R-Tech, Questcor, Avanir
This article was originally published in Scrip
Executive Summary
Amarin cuts half of staff; Sucampo partner R-Tech starts Phase III study in Japan; Questcor begins second Acthar Phase II study this year; and Avanir initiates Phase II Parkinson's study.